Lorraine Williamson
In a landmark move, the Spanish government has passed its most significant pharmaceutical reform since the 1990s. The new medicines law aims to reduce costs, promote competition, and improve access to innovative treatments.
While the reform has sparked optimism for some, others in the healthcare sector are raising concerns about its potential consequences.
Key changes under the new medicines law in Spain
The legislation introduces a flexible pricing model for off-patent medicines. This will allow manufacturers to submit price offers every six months within a set ‘bandwidth’. Medicines will now be categorised into three groups: the cheapest option, a group of selected medicines with fixed prices, and those not publicly funded. Pharmacies must dispense the lowest-cost option unless a patient specifies otherwise.
The new law also includes measures to combat medicine shortages by reinforcing supply chain resilience. Spanish Health Minister Mónica García has described the reform as crucial for creating a more efficient healthcare system.
Following the law’s approval, García posted on X (formerly Twitter):
“GREEN LIGHT! New Drug Law for the first time in 35 years:
– We ensure more affordable prices for both citizens and the healthcare system.
– We guarantee the supply of essential medicines.
– We accelerate the incorporation of innovative drugs.”
Her post highlights the government’s intent to not only cut pharmaceutical costs but also to secure access to both essential and cutting-edge treatments.
The pharmaceutical industry’s concerns
However, the reform has not been universally welcomed. Farmaindustria, the pharmaceutical trade association, warns that the pricing model could worsen supply problems, disrupt ongoing treatments, and discourage future investment. The industry argues that reduced profitability may slow down innovation and limit Spain’s competitiveness in the global pharmaceutical market.
Nurses gain more autonomy
One of the more progressive aspects of the new law is the expanded role of nurses. For the first time, nurses in Spain can prescribe medicines within their professional scope. The Consejo General de Enfermería has welcomed this development, viewing it as long overdue recognition of nursing expertise and a step toward a more efficient care system.
Public reaction and healthcare implications
The law introduces opportunities to modernise Spain’s healthcare services, particularly through price flexibility and enhanced roles for healthcare professionals. But the government must also manage the risks raised by industry leaders.
Public concern is growing. On April 5, tens of thousands protested across Andalucia against what they see as the ongoing decline of the public health system. The demonstrations are among the largest in the region since Spain’s return to democracy. Protesters are calling for better investment, improved conditions, and greater transparency in healthcare reforms.
Spain’s new medicines law is ambitious. It could make medicines more accessible and healthcare delivery more agile. Yet its success depends on careful implementation, investment in public services, and open dialogue with all stakeholders—including those with concerns about the economic and practical impact of the changes.